Surrozen Dividends and Buybacks

Dividend criteria checks 0/6

Surrozen does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-11.2%

Buyback Yield

Total Shareholder Yield	-11.2%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

Recent updates

Analysis Article • Jan 06

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Jan 03

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Jun 19

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Feb 12

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Oct 06

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen (NASDAQ:SRZN) on Thursday said it had entered into a collaboration and licensing agreement with German pharmaceutical firm Boehringer Ingelheim for its antibody SZN-413 for the treatment of eye diseases. SRZN stock +12.5% to $2.43 in premarket trading. This is the first partnership that SRZN had entered for one of its compounds, the company said in a statement. As per the terms of the deal, SRZN will get an upfront payment of $12.5M from Boehringer. Boehringer will get an exclusive, worldwide license to develop SZN-413. SRZN will be eligible to get up to $586.5M in milestone payments and royalties on sales.

Seeking Alpha • Aug 11

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen press release (NASDAQ:SRZN): Q2 GAAP EPS of -$0.40 beats by $0.06. Cash, cash equivalents and marketable securities for the Q2 were $92.7 million

Seeking Alpha • Oct 14

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. CEO Craig Parker, an industry veteran, joined us to discuss why there's no such thing as being too well capitalized in the biotech industry. 'We were really excited to complete a SPAC PIPE transaction that funds us through some of these Phase IB milestones in 2024.'

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SRZN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRZN's dividend payments have been increasing.

Dividend Yield vs Market

Surrozen Dividend Yield vs Market

How does SRZN dividend yield compare to the market?
Segment	Dividend Yield
Company (SRZN)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.3%
Industry Average (Biotechs)	2.4%
Analyst forecast (SRZN) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate SRZN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRZN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SRZN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SRZN has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 12:59
End of Day Share Price	2026/05/14 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Surrozen, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tazeen Ahmad	BofA Global Research
Steven Seedhouse	Cantor Fitzgerald & Co.
Yatin Suneja	Guggenheim Securities, LLC

Surrozen Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Recent updates

Consensus revenue estimates increase by 19%, EPS downgraded

First quarter 2026 earnings released: US$11.65 loss per share (vs US$4.54 loss in 1Q 2025)

Insufficient new directors

Surrozen, Inc., Annual General Meeting, May 13, 2026

Full year 2025 earnings: EPS and revenues miss analyst expectations

Surrozen, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Surrozen, Inc./De Announces Resignation of Shao-Lee Lin from the Board of Directors, Effective January 26, 2026

Surrozen (NASDAQ:SRZN) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Third quarter 2025 earnings released: US$8.36 loss per share (vs US$0.44 loss in 3Q 2024)

Surrozen, Inc. Appoints Andrew Maleki as Principal Accounting Officer, Effective November 12, 2025

Surrozen, Inc. Announces CFO Changes

Surrozen, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Companies Like Surrozen (NASDAQ:SRZN) Are In A Position To Invest In Growth

New minor risk - Share price stability

Surrozen, Inc., Annual General Meeting, May 14, 2025

New major risk - Negative shareholders equity

Insufficient new directors

Surrozen, Inc. announced that it expects to receive $175 million in funding from The Column Group, LLC, StemPoint Capital LP, RA Capital Management, L.P. and other investors.

New major risk - Share price stability

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky

New major risk - Financial position

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Price target decreased by 45% to US$33.00

Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources